Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 462-470

  Hofman, F M ^a   Stathopoulos, A ^b   Kruse, C A ^c   Chen, T C ^a   Schijns, V E J C ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Dept of Neurosurgery   (Belgium)

^c BURNHAM INSTITUTE   (United States)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Allogeneic; Astrocytoma; Biotherapy; Brain tumor; CTL; Glioma; Immunization; Immunotherapy

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CDX110; COTARA; CPG OLIGODEOXYNUCLEOTIDE; DCVAX; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2; INTERLEUKIN 4; IODINE 131; RESIQUIMOD; TEMOZOLOMIDE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALLOGRAFT; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL ACTIVATION; CELL CULTURE; CELL THERAPY; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG BINDING; DRUG TARGETING; EFFECTOR CELL; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN;

EID: 78649837190     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009060462     Document Type: Article

References (101)

1. Itoh, K.; Yamada, A.; Mine, T.; Noguchi, M. Recent advances incancer vaccines: an overview. Jpn. J. Clin. Oncol., 2009, 39 (2), 73-80.
2. Steiner, H. H.; Bonsanto, M. M.; Beckhove, P.; Brysch, M.; Geletneky, K.; Ahmadi, R.; Schuele-Freyer, R.; Kremer, P.; Ranaie, G.; Matejic, D.; Bauer, H.; Kiessling, M.; Kunze, S.; Schirrmacher, V.; Herold-Mende, C. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assessfeasibility, safety, and clinical benefit. J. Clin. Oncol., 2004, 22(21), 4272-4281.
3. Wheeler, C. J.; Black, K. L.; Liu, G.; Mazer, M.; Zhang, X. X.; Pepkowitz, S.; Goldfinger, D.; Ng, H.; Irvin, D.; Yu, J. S.Vaccination elicits correlated immune and clinical responses inglioblastoma multiforme patients. Cancer Res., 2008, 68 (14), 5955-5964.
4. Gomez, G. G.; Kruse, C. A. Mechanisms of malignant gliomaimmune resistance and sources of immunosuppression. Gene Ther.Mol. Biol., 2006, 10 (A), 133-146.
5. Dix, A. R.; Brooks, W. H.; Roszman, T. L.; Morford, L. A.Immune defects observed in patients with primary malignant braintumors. J. Neuroimmunol., 1999, 100 (1-2), 216-232.
6. El Andaloussi, A.; Lesniak, M. S. An increase inCD4+CD25+FOXP3+ regulatory T cells in tumor-infiltratinglymphocytes of human glioblastoma multiforme. Neuro. Oncol., 2006, 8 (3), 234-243.
7. Grauer, O. M.; Molling, J. W.; Bennink, E.; Toonen, L. W.; Sutmuller, R. P.; Nierkens, S.; Adema, G. J. TLR ligands in thelocal treatment of established intracerebral murine gliomas. J.Immunol., 2008, 181 (10), 6720-6729.
8. Fecci, P. E.; Mitchell, D. A.; Whitesides, J. F.; Xie, W.; Friedman, A. H.; Archer, G. E.; Herndon, J. E., 2nd; Bigner, D. D.; Dranoff, G.; Sampson, J. H. Increased regulatory T-cell fraction amidst adiminished CD4 compartment explains cellular immune defects inpatients with malignant glioma. Cancer Res., 2006, 66 (6), 3294-3302.
9. Liau, L. M.; Prins, R. M.; Kiertscher, S. M.; Odesa, S. K.; Kremen, T. J.; Giovannone, A. J.; Lin, J. W.; Chute, D. J.; Mischel, P. S.; Cloughesy, T. F.; Roth, M. D. Dendritic cell vaccination inglioblastoma patients induces systemic and intracranial T-cellresponses modulated by the local central nervous system tumormicroenvironment. Clin. Cancer Res., 2005, 11 (15), 5515-5525.
10. Deorah, S.; Lynch, C. F.; Sibenaller, Z. A.; Ryken, T. C. Trends inbrain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to2001. Neurosurg. Focus, 2006, 20 (4), E1.
11. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvanttemozolomide for glioblastoma. N. Engl. J. Med., 2005, 352 (10), 987-996.
12. Koukourakis, G. V.; Kouloulias, V.; Zacharias, G.; Papadimitriou, C.; Pantelakos, P.; Maravelis, G.; Fotineas, A.; Beli, I.; Chaldeopoulos, D.; Kouvaris, J. Temozolomide with radiationtherapy in high grade brain gliomas: pharmaceuticalsconsiderations and efficacy; a review article. Molecules, 2009, 14(4), 1561-1577.
13. Starnes, C. O. Coley's toxins in perspective. Nature, 1992, 357(6373), 11-12.
14. Coley, W. B. The treatment of malignant tumors by repeatedinoculations of erysipelas. With a report of ten original cases. 1893.Clin. Orthop. Relat. Res., 1991, (262), 3-11.
15. Hall, S. S. A commotion in the Blood: Life, death and the immunesystem. Holt Paperbacks 1997.
16. Mahaley, M. S., Jr.; Gillespie, G. Y. Immunotherapy of patientswith glioma: fact, fancy, and future. Prog. Exp. Tumor Res., 1984, 28, 118-135.
17. Bloom, W. H.; Carstairs, K. C.; Crompton, M. R.; Mc, K. W.Autologous glioma transplantation. Lancet, 1960, 2 (7141), 77-78.
18. Trouillas, P.; Lapras, C. Active immunotherapy of cerebral tumor.20 cases. Neurochirurgie, 1970, 16 (2), 143-170.
19. Read, S. B.; Kulprathipanja, N. V.; Gomez, G. G.; Paul, D. B.; Winston, K. R.; Robbins, J. M.; Kruse, C. A. Human alloreactiveCTL interactions with gliomas and with those having upregulatedHLA expression from exogenous IFN-gamma or IFN-gamma genemodification. J Interferon Cytokine Res., 2003, 23 (7), 379-393.
20. Parney, I. F.; Hao, C.; Petruk, K. C. Glioma immunology and immunotherapy. Neurosurgery, 2000, 46 (4), 778-791; discussion791-772.
21. Perez-Diez, A.; Joncker, N. T.; Choi, K.; Chan, W. F.; Anderson, C. C.; Lantz, O.; Matzinger, P. CD4 cells can be more efficient attumor rejection than CD8 cells. Blood, 2007, 109 (12), 5346-5354.
22. Neuwelt, E. A.; Clark, K.; Kirkpatrick, J. B.; Toben, H. Clinicalstudies of intrathecal autologous lymphocyte infusions in patientswith malignant glioma: a toxicity study. Ann. Neurol., 1978, 4 (4), 307-312.
23. Kruse, C.A.; Merchant, R.E. Cellular Therapy of Brain Tumors: Clinical Trials Futura Publ. Co.: Armonk, NY, 1997; pp. 487-504.
24. Paul, D. B.; Kruse, C. A. Immunologic approaches to therapy forbrain tumors. Curr. Neurol. Neurosci. Rep., 2001, 1 (3), 238-244.
25. Plautz, G. E.; Miller, D. W.; Barnett, G. H.; Stevens, G. H.; Maffett, S.; Kim, J.; Cohen, P. A.; Shu, S. T cell adoptiveimmunotherapy of newly diagnosed gliomas. Clin. Cancer Res., 2000, 6 (6), 2209-2218.
26. Tsuboi, K.; Saijo, K.; Ishikawa, E.; Tsurushima, H.; Takano, S.; Morishita, Y.; Ohno, T. Effects of local injection of ex vivoexpanded autologous tumor-specific T lymphocytes in cases withrecurrent malignant gliomas. Clin. Cancer Res., 2003, 9 (9), 3294-3302.
27. Rosenberg, S. A. Overcoming obstacles to the effectiveimmunotherapy of human cancer. Proc. Natl. Acad. Sci. USA, 2008, 105 (35), 12643-12644.
28. Mahaley, M. S., Jr.; Bigner, D. D.; Dudka, L. F.; Wilds, P. R.; Williams, D. H.; Bouldin, T. W.; Whitaker, J. N.; Bynum, J. M.Immunobiology of primary intracranial tumors. Part 7: Activeimmunization of patients with anaplastic human glioma cells: apilot study. J. Neurosurg., 1983, 59 (2), 201-207.
29. Okada, H.; Kohanbash, G.; Zhu, X.; Kastenhuber, E. R.; Hoji, A.; Ueda, R.; Fujita, M. Immunotherapeutic approaches for glioma.Crit. Rev. Immunol., 2009, 29 (1), 1-42.
30. Zhang, J. G.; Eguchi, J.; Kruse, C. A.; Gomez, G. G.; Fakhrai, H.; Schroter, S.; Ma, W.; Hoa, N.; Minev, B.; Delgado, C.; Wepsic, H.T.; Okada, H.; Jadus, M. R. Antigenic profiling of glioma cells togenerate allogeneic vaccines or dendritic cell-based therapeutics.Clin. Cancer Res., 2007, 13 (2 Pt 1), 566-575.
31. Zhang, J. G.; Kruse, C. A.; Driggers, L.; Hoa, N.; Wisoff, J.; Allen, J. C.; Zagzag, D.; Newcomb, E. W.; Jadus, M. R. Tumor antigenprecursor protein profiles of adult and pediatric brain tumorsidentify potential targets for immunotherapy. J. Neurooncol., 2008, 88 (1), 65-76.
32. Phillips, H. S.; Kharbanda, S.; Chen, R.; Forrest, W. F.; Soriano, R.H.; Wu, T. D.; Misra, A.; Nigro, J. M.; Colman, H.; Soroceanu, L.; Williams, P. M.; Modrusan, Z.; Feuerstein, B. G.; Aldape, K.Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages inneurogenesis. Cancer Cell, 2006, 9 (3), 157-173.
33. Liang, Y.; Diehn, M.; Watson, N.; Bollen, A. W.; Aldape, K. D.; Nicholas, M. K.; Lamborn, K. R.; Berger, M. S.; Botstein, D.; Brown, P. O.; Israel, M. A. Gene expression profiling revealsmolecularly and clinically distinct subtypes of glioblastomamultiforme. Proc. Natl. Acad. Sci. USA, 2005, 102 (16), 5814-5819.
34. Huse, J. T.; Holland, E. C. Targeting brain cancer: advances in themolecular pathology of malignant glioma and medulloblastoma.Nat. Rev. Cancer, 2010, 10 (5), 319-331.
35. Cancer Genome Atlas Research Networks. Comprehensivegenomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455 (7216), 1061-1068.
36. Chi, D. D.; Merchant, R. E.; Rand, R.; Conrad, A. J.; Garrison, D.; Turner, R.; Morton, D. L.; Hoon, D. S. Molecular detection of tumor-associated antigens shared by human cutaneous melanomasand gliomas. Am. J. Pathol., 1997, 150 (6), 2143-2152.
37. Kurpad, S. N.; Zhao, X. G.; Wikstrand, C. J.; Batra, S. K.; McLendon, R. E.; Bigner, D. D. Tumor antigens in astrocyticgliomas. Glia, 1995, 15 (3), 244-256.
38. Schijns, V. E. Immunological concepts of vaccine adjuvantactivity. Curr. Opin. Immunol., 2000, 12 (4), 456-463.
39. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y. J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells.Annu. Rev. Immunol., 2000, 18, 767-811.
40. Cerundolo, V.; Hermans, I. F.; Salio, M. Dendritic cells: a journeyfrom laboratory to clinic. Nat. Immunol., 2004, 5 (1), 7-10.
41. De Vleeschouwer, S.; Fieuws, S.; Rutkowski, S.; Van Calenbergh, F.; Van Loon, J.; Goffin, J.; Sciot, R.; Wilms, G.; Demaerel, P.; Warmuth-Metz, M.; Soerensen, N.; Wolff, J. E.; Wagner, S.; Kaempgen, E.; Van Gool, S. W. Postoperative adjuvant dendriticcell-based immunotherapy in patients with relapsed glioblastomamultiforme. Clin. Cancer Res., 2008, 14 (10), 3098-3104.
42. Ardon, H.; Van Gool, S.; Lopes, I. S.; Maes, W.; Sciot, R.; Wilms, G.; Demaerel, P.; Bijttebier, P.; Claes, L.; Goffin, J.; VanCalenbergh, F.; De Vleeschouwer, S. Integration of autologousdendritic cell-based immunotherapy in the primary treatment forpatients with newly diagnosed glioblastoma multiforme: a pilotstudy. J. Neurooncol., 2010, 99 (2), 261-272.
43. Rutkowski, S.; De Vleeschouwer, S.; Kaempgen, E.; Wolff, J. E.; Kuhl, J.; Demaerel, P.; Warmuth-Metz, M.; Flamen, P.; VanCalenbergh, F.; Plets, C.; Sorensen, N.; Opitz, A.; Van Gool, S. W.Surgery and adjuvant dendritic cell-based tumour vaccination forpatients with relapsed malignant glioma, a feasibility study. Br. J.Cancer, 2004, 91 (9), 1656-1662.
44. Yu, J. S.; Liu, G.; Ying, H.; Yong, W. H.; Black, K. L.; Wheeler, C. J. Vaccination with tumor lysate-pulsed dendritic cells elicitsantigen-specific, cytotoxic T-cells in patients with malignantglioma. Cancer Res., 2004, 64 (14), 4973-4979.
45. Okada, H.; Lieberman, F. S.; Edington, H. D.; Witham, T. F.; Wargo, M. J.; Cai, Q.; Elder, E. H.; Whiteside, T. L.; Schold, S. C., Jr.; Pollack, I. F. Autologous glioma cell vaccine admixed withinterleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with afavorable response to therapy. J. Neurooncol., 2003, 64 (1-2), 13-20.
46. Siesjo, P.; Visse, E.; Sjogren, H. O. Cure of established, intracerebral rat gliomas induced by therapeutic immunizationswith tumor cells and purified APC or adjuvant IFN-gammatreatment. J. Immunother. Emphasis Tumor Immunol., 1996, 19 (5), 334-345.
47. Schijns, V. E.; Degen, W. G. Vaccine immunopotentiators of thefuture. Clin. Pharmacol. Ther., 2007, 82 (6), 750-755.
48. Nishimura, F.; Dusak, J. E.; Eguchi, J.; Zhu, X.; Gambotto, A.; Storkus, W. J.; Okada, H. Adoptive transfer of type 1 CTLmediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res., 2006, 66(8), 4478-4487.
49. Qiao, Y.; Liu, B.; Li, Z. Activation of NK cells by extracellularheat shock protein 70 through induction of NKG2D ligands ondendritic cells. Cancer Immunol., 2008, 8, 12.
50. Grauer, O. M.; Nierkens, S.; Bennink, E.; Toonen, L. W.; Boon, L.; Wesseling, P.; Sutmuller, R. P.; Adema, G. J. CD4+FoxP3+regulatory T cells gradually accumulate in gliomas during tumorgrowth and efficiently suppress antiglioma immune responses invivo. Int. J. Cancer, 2007, 121 (1), 95-105.
51. Okada, H.; Lieberman, F. S.; Walter, K. A.; Lunsford, L. D.; Kondziolka, D. S.; Bejjani, G. K.; Hamilton, R. L.; Torres-Trejo, A.; Kalinski, P.; Cai, Q.; Mabold, J. L.; Edington, H. D.; Butterfield, L. H.; Whiteside, T. L.; Potter, D. M.; Schold, S. C., Jr.; Pollack, I. F. Autologous glioma cell vaccine admixed withinterleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J. Transl. Med., 2007, 5, 67.
52. O'Hagan, D. T.; Schijns, V. E., Immunopotentiators in ModernVaccines. In Immunopotentiators in Modern Vaccines, ElsevierScience & Technology, USA: 2005.
53. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P. H.; Trajanoski, Z.; Fridman, W. H.; Pages, F. Type, density, and location of immunecells within human colorectal tumors predict clinical outcome.Science, 2006, 313 (5795), 1960-1964.
54. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as aprognostic factor in human colorectal cancer. Cancer Res., 1998, 58 (16), 3491-3494.
55. Zhang, L.; Conejo-Garcia, J. R.; Katsaros, D.; Gimotty, P. A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M. N.; Rubin, S. C.; Coukos, G.Intratumoral T cells, recurrence, and survival in epithelial ovariancancer. N. Engl. J. Med., 2003, 348 (3), 203-213.
56. Nakano, O.; Sato, M.; Naito, Y.; Suzuki, K.; Orikasa, S.; Aizawa, M.; Suzuki, Y.; Shintaku, I.; Nagura, H.; Ohtani, H. Proliferativeactivity of intratumoral CD8(+) T-lymphocytes as a prognosticfactor in human renal cell carcinoma: clinicopathologicdemonstration of antitumor immunity. Cancer Res., 2001, 61 (13), 5132-5136.
57. Vesalainen, S.; Lipponen, P.; Talja, M.; Syrjanen, K. Histologicalgrade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostaticadenocarcinoma. Eur. J. Cancer, 1994, 30A (12), 1797-1803.
58. Marrogi, A. J.; Munshi, A.; Merogi, A. J.; Ohadike, Y.; El-Habashi, A.; Marrogi, O. L.; Freeman, S. M. Study of tumorinfiltrating lymphocytes and transforming growth factor-beta asprognostic factors in breast carcinoma. Int. J. Cancer, 1997, 74 (5), 492-501.
59. Vollmer, J.; Krieg, A. M. Immunotherapeutic applications of CpGoligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev., 2009, 61 (3), 195-204.
60. Scheel, B.; Aulwurm, S.; Probst, J.; Stitz, L.; Hoerr, I.; Rammensee, H. G.; Weller, M.; Pascolo, S. Therapeutic anti-tumorimmunity triggered by injections of immunostimulating singlestrandedRNA. Eur. J. Immunol., 2006, 36 (10), 2807-2816.
61. Schon, M. P.; Schon, M. TLR7 and TLR8 as targets in cancertherapy. Oncogene, 2008, 27 (2), 190-199.
62. Jensen, R.; Shan, J.; Freimark, B.; Harris, D.; King, S.; Lai, J.; Parseghian, M. Clinical Update: treatment of glioblastomamultiforme with radiolabeled antibodies that target tumor necrosis.Curr. Cancer Ther. Rev., 2010, 6, 13-18.
63. Li, J.; Hu, P.; Khawli, L. A.; Epstein, A. L. LEC/chTNT-3 fusionprotein for the immunotherapy of experimental solid tumors. J.Immunother., 2003, 26 (4), 320-331.
64. Apostolidis, L.; Schirrmacher, V.; Fournier, P. Host mediated antitumoreffect of oncolytic Newcastle disease virus after locoregionalapplication. Int. J. Oncol., 2007, 31 (5), 1009-1019.
65. Hoffmann, D.; Bayer, W.; Wildner, O. Local and distant immunemediatedcontrol of colon cancer growth with fusogenic membraneglycoproteins in combination with viral oncolysis. Hum. GeneTher., 2007, 18 (5), 435-450.
66. Ha, S. J.; West, E. E.; Araki, K.; Smith, K. A.; Ahmed, R.Manipulating both the inhibitory and stimulatory immune systemtowards the success of therapeutic vaccination against chronic viralinfections. Immunol. Rev., 2008, 223, 317-333.
67. Phan, G. Q.; Yang, J. C.; Sherry, R. M.; Hwu, P.; Topalian, S. L.; Schwartzentruber, D. J.; Restifo, N. P.; Haworth, L. R.; Seipp, C.A.; Freezer, L. J.; Morton, K. E.; Mavroukakis, S. A.; Duray, P. H.; Steinberg, S. M.; Allison, J. P.; Davis, T. A.; Rosenberg, S. A.Cancer regression and autoimmunity induced by cytotoxic Tlymphocyte-associated antigen 4 blockade in patients withmetastatic melanoma. Proc. Natl. Acad. Sci. USA, 2003, 100 (14), 8372-8377.
68. Zhang, L.; Gajewski, T. F.; Kline, J. PD-1/PD-L1 interactionsinhibit antitumor immune responses in a murine acute myeloidleukemia model. Blood, 2009, 114 (8), 1545-1552.
69. Dotti, G. Blocking PD-1 in cancer immunotherapy. Blood, 2009, 114 (8), 1457-1458.
70. Ahmadzadeh, M.; Johnson, L. A.; Heemskerk, B.; Wunderlich, J.R.; Dudley, M. E.; White, D. E.; Rosenberg, S. A. Tumor antigenspecificCD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 2009, 114 (8), 1537-1544.
71. Blackburn, S. D.; Shin, H.; Freeman, G. J.; Wherry, E. J. Selectiveexpansion of a subset of exhausted CD8 T cells by alphaPD-L1blockade. Proc. Natl. Acad. Sci. USA, 2008, 105 (39), 15016-15021.
72. Thomas, D. A.; Massague, J. TGF-beta directly targets cytotoxic Tcell functions during tumor evasion of immune surveillance.Cancer Cell, 2005, 8 (5), 369-380.
73. Dannull, J.; Su, Z.; Rizzieri, D.; Yang, B. K.; Coleman, D.; Yancey, D.; Zhang, A.; Dahm, P.; Chao, N.; Gilboa, E.; Vieweg, J.Enhancement of vaccine-mediated antitumor immunity in cancerpatients after depletion of regulatory T cells. J. Clin. Invest., 2005, 115 (12), 3623-3633.
74. Strauss, L.; Bergmann, C.; Szczepanski, M.; Gooding, W.; Johnson, J. T.; Whiteside, T. L. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in thetumor microenvironment. Clin. Cancer Res., 2007, 13 (15 Pt 1), 4345-4354.
75. Ahlers, J. D.; Belyakov, I. M.; Terabe, M.; Koka, R.; Donaldson, D. D.; Thomas, E. K.; Berzofsky, J. A. A push-pull approach tomaximize vaccine efficacy: abrogating suppression with an IL-13inhibitor while augmenting help with granulocyte/macrophagecolony-stimulating factor and CD40L. Proc. Natl. Acad. Sci. USA, 2002, 99 (20), 13020-13025.
76. Gomez, G. G.; Hutchison, R. B.; Kruse, C. A. Chemoimmunotherapyand chemo-adoptive immunotherapy of cancer.Cancer Treat. Rev., 2001, 27 (6), 375-402.
77. Gomez, G. G.; Varella-Garcia, M.; Kruse, C. A. Isolation of immunoresistant human glioma cell clones after selection withalloreactive cytotoxic T lymphocytes: cytogenetic and molecularcytogenetic characterization. Cancer Genet Cytogenet., 2006, 165(2), 121-134.
78. Paliogianni, F.; Boumpas, D. T. Glucocorticoids regulatecalcineurin-dependent trans-activating pathways for interleukin-2gene transcription in human T lymphocytes. Transplantation, 1995, 59 (9), 1333-1339.
79. Varesio, L.; Holden, H. T.; Taramelli, D. Mechanism of lymphocyte activation. II. Requirements for macromolecularsynthesis in the production of lymphokines. J. Immunol., 1980, 125(6), 2810-2817.
80. Wei, J.; Barr, J.; Kong, L. Y.; Wang, Y.; Wu, A.; Sharma, A. K.; Gumin, J.; Henry, V.; Colman, H.; Priebe, W.; Sawaya, R.; Lang, F. F.; Heimberger, A. B. Glioblastoma cancer-initiating cellsinhibit T-cell proliferation and effector responses by the signaltransducers and activators of transcription 3 pathway. Mol. CancerTher., 2010, 9 (1), 67-78.
81. Kjellman, C.; Olofsson, S. P.; Hansson, O.; Von Schantz, T.; Lindvall, M.; Nilsson, I.; Salford, L. G.; Sjogren, H. O.; Widegren, B. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int. J.Cancer, 2000, 89 (3), 251-258.
82. Gomez, G. G.; Kruse, C. A. Cellular and functionalcharacterization of immunoresistant human glioma cell clonesselected with alloreactive cytotoxic T lymphocytes reveals their upregulatedsynthesis of biologically active TGF-beta. J.Immunother., 2007, 30 (3), 261-273.
83. Bettini, M.; Vignali, D. A. Regulatory T cells and inhibitorycytokines in autoimmunity. Curr. Opin. Immunol., 2009, 21 (6), 612-618.
84. Fontana, A.; Kristensen, F.; Dubs, R.; Gemsa, D.; Weber, E.Production of prostaglandin E and an interleukin-1 like factor bycultured astrocytes and C6 glioma cells. J. Immunol., 1982, 129 (6), 2413-2419.
85. Sawamura, Y.; Diserens, A. C.; de Tribolet, N. In vitroprostaglandin E2 production by glioblastoma cells and its effect oninterleukin-2 activation of oncolytic lymphocytes. J. Neurooncol., 1990, 9 (2), 125-130.
86. Gabrilovich, D. I.; Chen, H. L.; Girgis, K. R.; Cunningham, H. T.; Meny, G. M.; Nadaf, S.; Kavanaugh, D.; Carbone, D. P. Productionof vascular endothelial growth factor by human tumors inhibits thefunctional maturation of dendritic cells. Nat. Med., 1996, 2 (10), 1096-1103.
87. Tarhini, A. A.; Iqbal, F. CTLA-4 blockade: therapeutic potential incancer treatments. Oncol. Targets Ther., 2010, 3, 15-25.
88. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. Evidence for atumoral immune resistance mechanism based on tryptophandegradation by indoleamine 2, 3-dioxygenase. Nat. Med., 2003, 9(10), 1269-1274.
89. Stathopoulos, A.; Samuelson, C.; Milbouw, G.; Hermanne, J. P.; Schijns, V. E.; Chen, T. C. Therapeutic vaccination againstmalignant gliomas based on allorecognition and syngeneic tumorantigens: proof of principle in two strains of rat. Vaccine, 2008, 26(14), 1764-1772.
90. Limaye, A. P.; Kirby, K. A.; Rubenfeld, G. D.; Leisenring, W. M.; Bulger, E. M.; Neff, M. J.; Gibran, N. S.; Huang, M. L.; SantoHayes, T. K.; Corey, L.; Boeckh, M. Cytomegalovirus reactivationin critically ill immunocompetent patients. JAMA, 2008, 300 (4), 413-422.
91. Scheurer, M. E.; Bondy, M. L.; Aldape, K. D.; Albrecht, T.; El-Zein, R. Detection of human cytomegalovirus in differenthistological types of gliomas. Acta Neuropathol., 2008, 116 (1), 79-86.
92. Mitchell, D. A.; Xie, W.; Schmittling, R.; Learn, C.; Friedman, A.; McLendon, R. E.; Sampson, J. H. Sensitive detection of humancytomegalovirus in tumors and peripheral blood of patientsdiagnosed with glioblastoma. Neuro Oncol., 2008, 10 (1), 10-18.
93. Kruse, C. A.; Mitchell, D. H.; Lillehei, K. O.; Johnson, S. D.; McCleary, E. L.; Moore, G. E.; Waldrop, S.; Mierau, G. W.Interleukin-2-activated lymphocytes from brain tumor patients. Acomparison of two preparations generated in vitro. Cancer, 1989, 64 (8), 1629-1637.
94. Li, G.; Mitra, S.; Wong, A. J. The epidermal growth factor variantIII peptide vaccine for treatment of malignant gliomas. Neurosurg.Clin. N Am, 2010, 21 (1), 87-93.
95. Heimberger, A. B.; Sampson, J. H. The PEPvIII-KLH (CDX-110)vaccine in glioblastoma multiforme patients. Expert Opin. Biol.Ther., 2009, 9 (8), 1087-1098.
96. Wheeler, C. J.; Black, K. L. DCVax-Brain and DC vaccines in thetreatment of GBM. Expert Opin. Investig. Drugs, 2009, 18 (4), 509-519.
97. Kahlon, K. S.; Brown, C.; Cooper, L. J.; Raubitschek, A.; Forman, S. J.; Jensen, M. C. Specific recognition and killing of glioblastomamultiforme by interleukin 13-zetakine redirected cytolytic T cells.Cancer Res., 2004, 64 (24), 9160-9166.
98. Bao, L.; Sun, Q.; Lucas, K. G. Rapid generation of CMV pp65-specific T cells for immunotherapy. J. Immunother., 2007, 30 (5), 557-561.
99. Kruse, C. A.; Rubinstein, D. Cytotoxic T Lymphocytes Reactive toPatient Major Histocompatibility Proteins for Therapy of RecurrentPrimary Brain Tumors. In Brain Tumor Immunotherapy, Liau, L.M.; Cloughesy, T. F.; Becker, D. P.; Bigner, D. D., Eds. HumanaPress: Totowa, 2001; pp. 149-170.
100. Nemunaitis, J.; Dillman, R. O.; Schwarzenberger, P. O.; Senzer, N.; Cunningham, C.; Cutler, J.; Tong, A.; Kumar, P.; Pappen, B.; Hamilton, C.; DeVol, E.; Maples, P. B.; Liu, L.; Chamberlin, T.; Shawler, D. L.; Fakhrai, H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modifiedallogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin.Oncol., 2006, 24 (29), 4721-4730.
101. Salcedo, M.; Bercovici, N.; Taylor, R.; Vereecken, P.; Massicard, S.; Duriau, D.; Vernel-Pauillac, F.; Boyer, A.; Baron-Bodo, V.; Mallard, E.; Bartholeyns, J.; Goxe, B.; Latour, N.; Leroy, S.; Prigent, D.; Martiat, P.; Sales, F.; Laporte, M.; Bruyns, C.; Romet-Lemonne, J. L.; Abastado, J. P.; Lehmann, F.; Velu, T. Vaccinationof melanoma patients using dendritic cells loaded with anallogeneic tumor cell lysate. Cancer Immunol. Immunother., 2006, 55 (7), 819-829.